Brief: Cereno Scientific Says Preclinical Data For Drug Candidate Cs585 Showing High Selectivity For The IP Receptor
16/06/2024 07:31
June 16 (Reuters) - Cereno Scientific AB CRNOSb.ST :
* PRECLINICAL DATA FOR CERENO SCIENTIFIC'S DRUG CANDIDATE
CS585
SHOWING HIGH SELECTIVITY FOR THE IP RECEPTOR PRESENTED AT THE
EHA 2024 HYBRID CONGRESS
Source text for Eikon: ID:nWkr9JMrNh
Further company coverage: CRNOSb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Carries Out Directed Share Issue Of SEK 60 Mln
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global